BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mirza Z, Karim S. Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges. Semin Cancer Biol 2021;69:226-37. [PMID: 31704145 DOI: 10.1016/j.semcancer.2019.10.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 37] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Sikder A, Vambhurkar G, Amulya E, Bagasariya D, Famta P, Shah S, Khatri DK, Singh SB, Sinha VR, Srivastava S. Advancements in redox-sensitive micelles as nanotheranostics: A new horizon in cancer management. J Control Release 2022;349:1009-30. [PMID: 35961470 DOI: 10.1016/j.jconrel.2022.08.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Zhong X, Dai X, Wang Y, Wang H, Qian H, Wang X. Copper-based nanomaterials for cancer theranostics. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2022;14:e1797. [PMID: 35419993 DOI: 10.1002/wnan.1797] [Reference Citation Analysis]
3 Xu M, Yang Y, Yuan Z. Breast Cancer Cell Membrane Camouflaged Lipid Nanoparticles for Tumor-Targeted NIR-II Phototheranostics. Pharmaceutics 2022;14:1367. [PMID: 35890265 DOI: 10.3390/pharmaceutics14071367] [Reference Citation Analysis]
4 Karimifard S, Rezaei N, Jamshidifar E, Moradi Falah Langeroodi S, Abdihaji M, Mansouri A, Hosseini M, Ahmadkhani N, Rahmati Z, Heydari M, Vosough M, Akbarzadeh I, Mostafavi E. pH-Responsive Chitosan-Adorned Niosome Nanocarriers for Co-Delivery of Drugs for Breast Cancer Therapy. ACS Appl Nano Mater . [DOI: 10.1021/acsanm.2c00861] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zheng S, Cai Y, Hong Y, Gong Y, Gao L, Li Q, Li L, Sun X. Legumain/pH dual-responsive lytic peptide-paclitaxel conjugate for synergistic cancer therapy. Drug Deliv 2022;29:1764-75. [PMID: 35638851 DOI: 10.1080/10717544.2022.2081380] [Reference Citation Analysis]
6 Li M, Cui X, Wei F, Li C, Han X. RGD Peptide Modified Erythrocyte Membrane/Porous Nanoparticles Loading Mir-137 for NIR-Stimulated Theranostics of Glioblastomas. Nanomaterials (Basel) 2022;12:1464. [PMID: 35564173 DOI: 10.3390/nano12091464] [Reference Citation Analysis]
7 Dhas N, García MC, Kudarha R, Pandey A, Nikam AN, Gopalan D, Fernandes G, Soman S, Kulkarni S, Seetharam RN, Tiwari R, Wairkar S, Pardeshi C, Mutalik S. Advancements in cell membrane camouflaged nanoparticles: A bioinspired platform for cancer therapy. J Control Release 2022:S0168-3659(22)00213-9. [PMID: 35439581 DOI: 10.1016/j.jconrel.2022.04.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Hulsurkar MM, Lahiri SK, Karch J, Wang MC, Wehrens XH. Targeting calcium-mediated inter-organellar crosstalk in cardiac diseases. Expert Opinion on Therapeutic Targets. [DOI: 10.1080/14728222.2022.2067479] [Reference Citation Analysis]
9 Koksharov YA, Gubin SP, Taranov IV, Khomutov GB, Gulyaev YV. Magnetic Nanoparticles in Medicine: Progress, Problems, and Advances. J Commun Technol Electron 2022;67:101-16. [DOI: 10.1134/s1064226922020073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Monaco F, De Conti L, Vodret S, Zanotta N, Comar M, Manzotti S, Rubini C, Graciotti L, Fulgenzi G, Bovenzi M, Baralle M, Tomasetti M, Santarelli L. Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126 induces tumour cell killing. Transl Oncol 2022;20:101400. [PMID: 35334283 DOI: 10.1016/j.tranon.2022.101400] [Reference Citation Analysis]
11 He Y, Fan X, Wu X, Hu T, Zhou F, Tan S, Chen B, Pan A, Liang S, Xu H. pH-Responsive size-shrinkable mesoporous silica-based nanocarriers for improving tumor penetration and therapeutic efficacy. Nanoscale 2022;14:1271-84. [PMID: 35006226 DOI: 10.1039/d1nr07513f] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ala M. Target c-Myc to treat pancreatic cancer. Cancer Biol Ther 2022;:1-17. [PMID: 34978469 DOI: 10.1080/15384047.2021.2017223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Khalil M, Haq EA, Dwiranti A, Prasedya ES, Kitamoto Y. Bifunctional folic-conjugated aspartic-modified Fe 3 O 4 nanocarriers for efficient targeted anticancer drug delivery. RSC Adv 2022;12:4961-71. [DOI: 10.1039/d1ra08776b] [Reference Citation Analysis]
14 Wang H, Shan S, Wang H, Wang X. CircATXN7 contributes to the progression and doxorubicin resistance of breast cancer via modulating miR-149-5p/HOXA11 pathway. Anticancer Drugs 2022;33:e700-10. [PMID: 34845164 DOI: 10.1097/CAD.0000000000001243] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Famta P, Shah S, Chatterjee E, Singh H, Dey B, Guru SK, Singh SB, Srivastava S. Exploring new Horizons in overcoming P-glycoprotein-mediated multidrug-resistant breast cancer via nanoscale drug delivery platforms. Curr Res Pharmacol Drug Discov 2021;2:100054. [PMID: 34909680 DOI: 10.1016/j.crphar.2021.100054] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
16 Nieves LM, Mossburg K, Hsu JC, Maidment ADA, Cormode DP. Silver chalcogenide nanoparticles: a review of their biomedical applications. Nanoscale 2021;13:19306-23. [PMID: 34783806 DOI: 10.1039/d0nr03872e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
17 Amani A, Dustparast M, Noruzpour M, Zakaria RA, Ebrahimi HA. Design and Invitro Characterization of Green Synthesized Magnetic Nanoparticles Conjugated with Multitargeted Poly Lactic Acid Copolymers for Co-delivery of siRNA and Paclitaxel. Eur J Pharm Sci 2021;167:106007. [PMID: 34520835 DOI: 10.1016/j.ejps.2021.106007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Loskutova K, Olofsson K, Hammarström B, Wiklund M, Svagan AJ, Grishenkov D. Measuring the Compressibility of Cellulose Nanofiber-Stabilized Microdroplets Using Acoustophoresis. Micromachines (Basel) 2021;12:1465. [PMID: 34945315 DOI: 10.3390/mi12121465] [Reference Citation Analysis]
19 Nitheesh Y, Pradhan R, Hejmady S, Taliyan R, Singhvi G, Alexander A, Kesharwani P, Dubey SK. Surface engineered nanocarriers for the management of breast cancer. Mater Sci Eng C Mater Biol Appl 2021;130:112441. [PMID: 34702526 DOI: 10.1016/j.msec.2021.112441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
20 Zhao M, Yang X, Fu H, Chen C, Zhang Y, Wu Z, Duan Y, Sun Y. Immune/Hypoxic Tumor Microenvironment Regulation-Enhanced Photodynamic Treatment Realized by pH-Responsive Phase Transition-Targeting Nanobubbles. ACS Appl Mater Interfaces 2021;13:32763-79. [PMID: 34235912 DOI: 10.1021/acsami.1c07323] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
21 Herdiana Y, Wathoni N, Shamsuddin S, Joni IM, Muchtaridi M. Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment. Polymers (Basel) 2021;13:1717. [PMID: 34074020 DOI: 10.3390/polym13111717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
22 Dobrucka R, Romaniuk-Drapała A, Kaczmarek M. Facile synthesis of Au/ZnO/Ag nanoparticles using Glechoma hederacea L. extract, and their activity against leukemia. Biomed Microdevices 2021;23:14. [PMID: 33683457 DOI: 10.1007/s10544-021-00557-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chen C, Shen M, Liao H, Guo Q, Fu H, Yu J, Duan Y. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer. J Nanobiotechnology 2021;19:55. [PMID: 33632232 DOI: 10.1186/s12951-021-00800-z] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
24 Valdivia G, Alonso-Diez Á, Pérez-Alenza D, Peña L. From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review. Front Vet Sci 2021;8:623800. [PMID: 33681329 DOI: 10.3389/fvets.2021.623800] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhang H, Wang J, Yin Y, Meng Q, Lyu Y. The role of EMT-related lncRNA in the process of triple-negative breast cancer metastasis. Biosci Rep 2021;41:BSR20203121. [PMID: 33443534 DOI: 10.1042/BSR20203121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
26 Li R, Da X, Li X, Lu Y, Gu F, Liu Y. Functionalized magnetic nanoparticles for drug delivery in tumor therapy*. Chinese Phys B 2021;30:017502. [DOI: 10.1088/1674-1056/abb3e6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
27 Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B 2021;11:55-70. [PMID: 33532180 DOI: 10.1016/j.apsb.2020.09.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 35.0] [Reference Citation Analysis]
28 Akhter MH, Beg S, Tarique M, Malik A, Afaq S, Choudhry H, Hosawi S. Receptor-based targeting of engineered nanocarrier against solid tumors: Recent progress and challenges ahead. Biochim Biophys Acta Gen Subj 2021;1865:129777. [PMID: 33130062 DOI: 10.1016/j.bbagen.2020.129777] [Cited by in Crossref: 1] [Cited by in F6Publishing: 11] [Article Influence: 0.5] [Reference Citation Analysis]
29 Xiao Y, Gao Y, Li F, Deng Z. Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients. Drug Deliv 2020;27:1491-500. [PMID: 33100060 DOI: 10.1080/10717544.2020.1822460] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
30 Tao J, Diao L, Chen F, Shen A, Wang S, Jin H, Cai D, Hu Y. pH-Sensitive Nanoparticles Codelivering Docetaxel and Dihydroartemisinin Effectively Treat Breast Cancer by Enhancing Reactive Oxidative Species-Mediated Mitochondrial Apoptosis. Mol Pharm 2021;18:74-86. [PMID: 33084332 DOI: 10.1021/acs.molpharmaceut.0c00432] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
31 Yuan Y, Jin P, Wang Y, Zhao X, Hu Q, Wu W, Huang J, Zhang N. A dendritic, redox-responsive, supramolecular (Dr.S) system for lysis-triggered delivery for drug-resistant renal cancer. RSC Adv 2020;10:37826-33. [PMID: 35515145 DOI: 10.1039/d0ra06444k] [Reference Citation Analysis]
32 Cihan YB. Nanoparticle-Based Radiosensitizers in Radiotherapy Applications. Cancer Biother Radiopharm 2021;36:305-6. [PMID: 32996779 DOI: 10.1089/cbr.2020.4211] [Reference Citation Analysis]
33 Hattab D, Bakhtiar A. Bioengineered siRNA-Based Nanoplatforms Targeting Molecular Signaling Pathways for the Treatment of Triple Negative Breast Cancer: Preclinical and Clinical Advancements. Pharmaceutics 2020;12:E929. [PMID: 33003468 DOI: 10.3390/pharmaceutics12100929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
34 Ji X, Han T, Kang N, Huang S, Liu Y. Preparation of RGD4C fused anti-TNFα nanobody and inhibitory activity on triple-negative breast cancer in vivo. Life Sci 2020;260:118274. [PMID: 32827545 DOI: 10.1016/j.lfs.2020.118274] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
35 Bhattacharjee A, Purkait MK, Gumma S. Loading and release of doxorubicin hydrochloride from iron(iii) trimesate MOF and zinc oxide nanoparticle composites. Dalton Trans 2020;49:8755-63. [PMID: 32555814 DOI: 10.1039/d0dt01730b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
36 Dai C, Zhang Y, Xu Z, Jin M. MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma. Cancer Cell Int 2020;20:98. [PMID: 32256207 DOI: 10.1186/s12935-020-01185-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
37 Roma-Rodrigues C, Rivas-García L, Baptista PV, Fernandes AR. Gene Therapy in Cancer Treatment: Why Go Nano? Pharmaceutics 2020;12:E233. [PMID: 32151052 DOI: 10.3390/pharmaceutics12030233] [Cited by in Crossref: 29] [Cited by in F6Publishing: 58] [Article Influence: 14.5] [Reference Citation Analysis]